StreetInsider.com News Articles

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

Tue, 18 Aug 2026 07:45:00 -0400

Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001)

96% reduction in preparation time and comparable clinical outcomes to allograft including graft take, wound healing, and safety

Multi-center randomized controlled study supports PermeaDerm as a clinically comparable, economically advantaged alternative to allograft for wound temporization with off-the-shelf availability and no requirements for thawing, meshing, or tissue tracking logistics

Management to host Key Opinion Leader webinar at 4:30 p.m. ET on August 18

VALENCIA, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- AVITA

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

Tue, 18 Aug 2026 07:45:00 -0400

Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001)

96% reduction in preparation time and comparable clinical outcomes to allograft including graft take, wound healing, and safety

Multi-center randomized controlled study supports PermeaDerm as a clinically comparable, economically advantaged alternative to allograft for wound temporization with off-the-shelf availability and no requirements for thawing, meshing, or tissue tracking logistics

Management to host Key Opinion Leader webinar at 4:30 p.m. ET on August 18

VALENCIA, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- AVITA

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

Tue, 18 Aug 2026 07:45:00 -0400

Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001)

96% reduction in preparation time and comparable clinical outcomes to allograft including graft take, wound healing, and safety

Multi-center randomized controlled study supports PermeaDerm as a clinically comparable, economically advantaged alternative to allograft for wound temporization with off-the-shelf availability and no requirements for thawing, meshing, or tissue tracking logistics

Management to host Key Opinion Leader webinar at 4:30 p.m. ET on August 18

VALENCIA, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- AVITA

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

Tue, 18 Aug 2026 07:45:00 -0400

Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001)

96% reduction in preparation time and comparable clinical outcomes to allograft including graft take, wound healing, and safety

Multi-center randomized controlled study supports PermeaDerm as a clinically comparable, economically advantaged alternative to allograft for wound temporization with off-the-shelf availability and no requirements for thawing, meshing, or tissue tracking logistics

Management to host Key Opinion Leader webinar at 4:30 p.m. ET on August 18

VALENCIA, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- AVITA

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

Tue, 18 Aug 2026 07:45:00 -0400

Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001)

96% reduction in preparation time and comparable clinical outcomes to allograft including graft take, wound healing, and safety

Multi-center randomized controlled study supports PermeaDerm as a clinically comparable, economically advantaged alternative to allograft for wound temporization with off-the-shelf availability and no requirements for thawing, meshing, or tissue tracking logistics

Management to host Key Opinion Leader webinar at 4:30 p.m. ET on August 18

VALENCIA, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- AVITA

AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes

Tue, 18 Aug 2026 07:45:00 -0400

Primary endpoint achieved, demonstrating a 70% economic advantage over allograft based on product cost per percent total body surface area treated (p<0.001)

96% reduction in preparation time and comparable clinical outcomes to allograft including graft take, wound healing, and safety

Multi-center randomized controlled study supports PermeaDerm as a clinically comparable, economically advantaged alternative to allograft for wound temporization with off-the-shelf availability and no requirements for thawing, meshing, or tissue tracking logistics

Management to host Key Opinion Leader webinar at 4:30 p.m. ET on August 18

VALENCIA, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- AVITA

AVITA Medical to Host Investor Webinar Briefing

Sun, 09 Aug 2026 18:00:00 -0400

VALENCIA, Calif., Aug. 09, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O’Toole, Chief Financial Officer, on August 12, 2026, at 4:00 p.m. Pacific Time (August 13, 2026, at 9:00 a.m. Australian Eastern Standard Time).

The webinar presentation will cover financial and business results from AVITA Medical’s recent second-quarter 2026 earnings webcast and will conclude with a Q&A session. Participants are

AVITA Medical to Host Investor Webinar Briefing

Sun, 09 Aug 2026 18:00:00 -0400

The webinar presentation will cover financial and business results from AVITA Medical’s recent second-quarter 2026 earnings webcast and will conclude with a Q&A session. Participants are

AVITA Medical to Host Investor Webinar Briefing

Sun, 09 Aug 2026 18:00:00 -0400

The webinar presentation will cover financial and business results from AVITA Medical’s recent second-quarter 2026 earnings webcast and will conclude with a Q&A session. Participants are

AVITA Medical to Host Investor Webinar Briefing

Sun, 09 Aug 2026 18:00:00 -0400

The webinar presentation will cover financial and business results from AVITA Medical’s recent second-quarter 2026 earnings webcast and will conclude with a Q&A session. Participants are

AVITA Medical to Host Investor Webinar Briefing

Sun, 09 Aug 2026 18:00:00 -0400

The webinar presentation will cover financial and business results from AVITA Medical’s recent second-quarter 2026 earnings webcast and will conclude with a Q&A session. Participants are

AVITA Medical to Host Investor Webinar Briefing

Sun, 09 Aug 2026 18:00:00 -0400

The webinar presentation will cover financial and business results from AVITA Medical’s recent second-quarter 2026 earnings webcast and will conclude with a Q&A session. Participants are

AVITA Medical Announces Participation at Canaccord Genuity Growth Conference

Fri, 07 Aug 2026 08:45:00 -0400

VALENCIA, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it will be participating at the Canaccord Genuity 46th Annual Growth Conference in Boston, taking place August 11–13, 2026.

AVITA Medical President and CEO Cary Vance will be speaking on Wednesday, August 12, 2026, at 8:00 a.m. Eastern Time. A live webcast and replay will be available under the Investor Relations Events & Presentations section of AVITA Medical’s website, at: https://ir.avitamedical.com/events-and-presentations

Investors

AVITA Medical Announces Participation at Canaccord Genuity Growth Conference

Fri, 07 Aug 2026 08:45:00 -0400

Investors

AVITA Medical Announces Participation at Canaccord Genuity Growth Conference

Fri, 07 Aug 2026 08:45:00 -0400

Investors

AVITA Medical Announces Participation at Canaccord Genuity Growth Conference

Fri, 07 Aug 2026 08:45:00 -0400

Investors

AVITA Medical Announces Participation at Canaccord Genuity Growth Conference

Fri, 07 Aug 2026 08:45:00 -0400

Investors

AVITA Medical Announces Participation at Canaccord Genuity Growth Conference

Fri, 07 Aug 2026 08:45:00 -0400

Investors

AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven